iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…
Author: Editor
Axi-cel: Zuma 7 was a randomized phase 3 study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to a standard of care,…
iFrame is not supported! Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a…
Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a 24 week trial. And…
LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed in 2013. It actually was the byproduct of my wife who’s a physician here in San Diego. And not only her experiences with her patients but also personal experiences that she had, people that she knew in the community, friends of hers. That really drove her to, looking for a solution and particularly for cancer patients. That wasn’t toxic, that wasn’t gonna destroy the patient’s lives. And there was actually a friend of hers, she was a single mother…
iFrame is not supported! SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been…
SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been stably transected with the…
Inherited Thrombophilia: Pregnancy & Heparin – Middeldorp, MD- ASH 2022 By Saskia Middeldorp, MD I’m able to present the results of the ALIFE2 trial for you today. For everyone tomorrow. This trial investigated low molecular weight heparin and standard pregnancy care.First, a standard pregnancy care alone for women with recurrent miscarriage and inherited forms of Thrombophilia. , we have previously shown that in unexplained recurrent miscarriage antithrombotic therapy with low molecular heparin or aspirin does not help. in women with Thrombophilia in that trial, however, we noticed a relative risk of 31.31, so 30% more chances of having a live…
Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine study today. By way of background, we note that Bruton tyrosine kinase inhibition and CLL has been transformative. Of its therapy because B-cell receptor signaling is required for tumor expansion and proliferation in CLL and B-cell lymphomas, and that B-cell receptor signaling is dependent on btk.Ibrutinib is the first in class covalent BTK inhibitor. Which did transform CLL therapy, but has properties that limit its use, particularly treatment discontinuation from toxicities with discontinuing rates of 16 to 23% across many…
Blinatumomab: ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial By Mark Litzow, MD ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial. This is a phase three randomized trial. Blinatumomab for newly diagnosed bcr A negative. We also refer to the bcr. Gene Rearrangement is a Philadelphia chromosome. So these patients were negative for this finding, but they had acute lymphoblastic leukemia. Acute lymphoblastic leukemias is the acute leukemia counterpart of what Dr.Brown just told you about chronic lymphocytic leukemia. And these are the detectable cancer cells that we worry about. These are the blast cells that don’t function. And cause…
iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with…
Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with a label for patients…
iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as…
Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as a treatment for patients…
iFrame is not supported! Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it…
Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it is resurrected. And…
iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In…
iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or…
Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In other words, maybe if…
Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or the degradation of these…
iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over…
Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over time we’re able to…
iFrame is not supported! Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies,…
Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies, of course, with early…
iFrame is not supported! Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in…
Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in the provincial setting, menopausal…
iFrame is not supported! Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of…
iFrame is not supported! Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free…
Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free survival, and the second…
iFrame is not supported! MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why…
iFrame is not supported! Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to…
iFrame is not supported! Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women…
Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of all 3 Akt isoforms.…
Francois-Clement Bidard, MD, PhD of Institut Curiediscusses Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer
MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why am I saying HER2+…
Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to prior endocrine therapy. So…
Yen-Shen Lu, MD of National Taiwan University discusses Ribociclib and the Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,
Getting description
Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women who enrolled in the…
HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, MD, UCLA Health discusses the released data for Phase 3 study entitled DESTINY-Breast03 at SABCS 2022
Trastuzumab deruxtecan DESTINY-Breast02 results presented at SABCS 2022 with Ian E. Krop, MD, PhD Yale School of Medicine.GS2-01: Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02 With Slides
SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02Sara Hurvitz, MD from UCLA Health discusses Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Aditya Bardia, MD, MPH from Massachusetts General Hospital discusses TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer
iFrame is not supported! Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial as opposed to current clinical practice standards? So for aggressive disease status, conventionally, doctors (healthcare professional) will try to prescribe chemotherapy instead of initial endocrine therapy based regimen. So for postmenopausal patients, single aging chemotherapy is preferred, But for premenopausal patients, doctors will consider that some of them have a more aggressive tumor biology, so the tumor may grow faster. Secondly, the patient may be more tolerant of the side effects of combination chemotherapy. So that…
Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial as opposed to current clinical practice standards? So for aggressive disease status, conventionally, doctors (healthcare professional) will try to prescribe chemotherapy instead of initial endocrine therapy based regimen. So for postmenopausal patients, single aging chemotherapy is preferred, But for premenopausal patients, doctors will consider that some of them have a more aggressive tumor biology, so the tumor may grow faster. Secondly, the patient may be more tolerant of the side effects of combination chemotherapy. So that is why combination chemotherapy…
iFrame is not supported! VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol (val-083), is a compound that came through the National Cancer Institute (NIC), which runs massive screens around the world looking for new cancer agents. And the NCI (National Cancer Institute) still performs those duties, even though there’s a large network of smaller and larger corporations now focused on oncology. So VAL-083 is a small molecule. And it’s unique in the sense that it’s a sugar that’s derived with reactive epoxide groups. And this small molecule has the ability to…
VAL-083: Dennis Brown [2022]: Key Facts To Consider Glioblastoma VAL-083, or it’s chemical name dianhydrogalactitol (val-083), is a compound that came through the National Cancer Institute (NIC), which runs massive screens around the world looking for new cancer agents. And the NCI (National Cancer Institute) still performs those duties, even though there’s a large network of smaller and larger corporations now focused on oncology. So VAL-083 is a small molecule. And it’s unique in the sense that it’s a sugar that’s derived with reactive epoxide groups. And this small molecule has the ability to cross the blood brain…
iFrame is not supported! Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this improve clinical outcomes? – Omidubicel is was developed as a stem cell source for use in patients who need an allogeneic stem cell transplant(stem cell transplantation). And these are patients with hematological malignancies like leukemia, myelodysplastic syndrome, lymphoma, and other diseases. Patients receiving omidubicel is derived from umbilical cord blood, which was identified years ago as a source of hematopoietic stem cells. But because of the size of (umbilical) cord blood, it often contains too few cells to serve…
Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this improve clinical outcomes? – Omidubicel is was developed as a stem cell source for use in patients who need an allogeneic stem cell transplant(stem cell transplantation). And these are patients with hematological malignancies like leukemia, myelodysplastic syndrome, lymphoma, and other diseases. Patients receiving omidubicel is derived from umbilical cord blood, which was identified years ago as a source of hematopoietic stem cells. But because of the size of (umbilical) cord blood, it often contains too few cells to serve as an effective transplant…